TITLE

Caspofungin: A Viewpoint by Helen Leather and John Wingard

AUTHOR(S)
Leather, H.; Wingard, J.
PUB. DATE
June 2001
SOURCE
Drugs;Jun2001, Vol. 61 Issue 8, p1130
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Comments on the effectiveness of caspofungin in the treatment of fungal infections. Classes of antifungals; Advantages of caspofungin; Clinical efficacy of caspofungin in the treatment of oesophageal and oropharyngeal candidiasis.
ACCESSION #
4745470

 

Related Articles

  • The Final Nail. Johnson, James R. // Clinical Infectious Diseases;7/1/2000, Vol. 31 Issue 1, p209 

    Comments on an article by J.D. Sobel, C.A. Kaufmann, D. McKinsey et al about antifungal therapy for asymptomatic candiduria. Outcome difference between the fluconazole and placebo groups; Absence of clinical benefit associated with treatment of asymptomatic funguria in nonseptic patients.

  • Itraconazole Prophylaxis for Fungal Infections in Patients with Advanced Human Immunodeficiency... McKinsey, David S.; Wheat, L. Joseph; Cloud, Gretchen A.; Pierce, Mark; Black, John R.; Bamberger, David M.; Goldman, Mitchell; Thomas, CArolynn J.; Gutsch, Heidi M.; Moskovitz, Bruce; Dismukes, William E.; Kauffman, Carol A. // Clinical Infectious Diseases;5/1/1999, Vol. 28 Issue 5, p1049 

    Evaluates the effect of itraconazole prophylaxis for fungal infections in a randomized, placebo-controlled, double-blind study of HIV-positive persons. Efficacy of itraconazole antifungal drug in preventing histoplasmosis and cryptococcosis in patients; Factors associated with prophylaxis...

  • PREVALENCE AND ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA SPECIES ISOLATED FROM TERTIARY CARE HOSPITAL IN NORTH EAST KARNATAKA. SUNILKUMAR BIRADAR; U. AMRUTHKISHAN; R. GANGANE; P. SHEEBA; N. AMAR; D. PRAVEEN; SREEKANTHA // International Journal of Pharma & Bio Sciences;Jan-Mar2013, Vol. 4 Issue 1, pB-1113 

    Introduction: Candida is a yeast like fungus causing commonest fungal infections. Being endogenous in nature, in individuals with risk factors can lead to candidiasis. Candidiasis caused by various species, important being C. albicans. As there are chronic, treatment failure cases noted in these...

  • Itraconazole Oral Solution as Prophylaxis for Fungal Infections in Neutropenic Patients with Hematologic Malignancies: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Menichetti, Francesco; Del Favero, Albano; Martino, Piero; Bucaneve, Giampaolo; Micozzi, Alessandra; Girmenia, Corrado; Barbabietola, Giuliana; Pagano, Livio; Leoni, Pietro; Specchia, Giorgina; Caiozzo, Alessandro; Raimondi, Roberto; Mandelli, Franco // Clinical Infectious Diseases;2/1/1999, Vol. 28 Issue 2, p250 

    To evaluate the efficacy and safety of itraconazole oral solution for preventing fungal infections, a randomized, placebo-controlled, double-blind, multicenter trial was conducted: 405 neutropenic patients with hematologic malignancies were randomly assigned to receive either itraconazole, 2.5...

  • High-dose fluconazole should reduce mortality at acceptable cost.  // PharmacoEconomics & Outcomes News;7/14/2007, Issue 532, p5 

    The article discusses a study on the administration of fluconazole therapy for treatment of invasive candidiasis among patients in the intensive care unit. Researchers concluded that empiric high-dose fluconazole therapy reduces mortality associated with aggressive candidiasis at an acceptable...

  • The effect of voriconazole and itraconazole on some biological characteristics of Candida strains isolated from hospitalized and ambulatory - treated patients. Kurnatowska, Agnieszka K.; Kwaƛniewska, Jolanta // Medical Mycology / Mikologia;2011, Vol. 18 Issue 4, p171 

    Introduction: The growing prevalence of fungi from various genera and species as well as strains exhibiting reduced susceptibility to some antifungal drugs, which may induce organs involving or generalized mycoses, has posed a serious problem in recent years. The efficacy of mycosis treatment...

  • Efficacy of micafungin in empirical therapy of deep mycosis in surgically ill patients. Okamoto, Kohji; Katsuki, Takefumi; Tamura, Toshihisa; Kanemitsu, Shuichi; Minagawa, Noritaka; Torigoe, Takayuki; Shibao, Kazunori; Higure, Aiichirou; Yamaguchi, Koji // Journal of Infection & Chemotherapy (Springer Science & Business;Oct2012, Vol. 18 Issue 5, p621 

    Micafungin (MCFG), an echinocandin antifungal agent, exhibits antifungal activity against Candida albicans and non- albicans Candida. The fungicidal activity of MCFG against clinical isolates of C andida species was investigated, and the clinical efficacy of MCFG in therapy of deep mycosis in...

  • Anidulafungin: A Viewpoint by William J. Steinbach. Steinbach, William J // Drugs;2004, Vol. 64 Issue 19, p2259 

    Presents the viewpoint of William J. Steinbach regarding the drug, anidulafungin. Description of the drug; Benefits offered by the drug; Advantages of anidulafungin over amphotericin B deoxycholate.

  • imidazole drugs. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p410 

    An encyclopedia entry for "imidazole drugs" is presented. It is a group of antifungal drugs that is utilized for the treatment of fungal infections including candidiasis and tinea.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics